IngentaConnect Cost-effectiveness analysis of lamivudine and adefovir dipivoxil ...

Authors: BUTI, M.¹; CASADO, M. A.²; CALLEJA, J. L.³; SALMERÓN, J.⁴; AGUILAR, J.⁵; RUEDA, M.⁶; ESTEBAN, R.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 23, Number 3, February 2006 , pp. 409-419(11)

Abstract:

Summary Aim

To estimate the cost-effectiveness over a 4-year duration of lamivudine and adefovir dipivoxil for patients with hepatitis B `e' antigen-negative chronic hepatitis B. Methods

A decision analysis model has been used to perform a cost-effectiveness analysis of lamivudine and adefovir dipivoxil from the perspective of the Spanish Public Health System. Data were obtained from clinical trials. Results

For the base-case, the total estimated cost per patient treated with lamivudine or adefovir dipivoxil for 4 years was €11 457 and €21 939 respectively. Virological response at year 4 for the lamivudine arm was 40.4% and 78.0% for the adefovir dipivoxil arm. The average cost-effectiveness ratio (cost per responding patient at year 4) was €28 375 for the lamivudine arm and €28 132 for the adefovir dipivoxil arm. The incremental cost-effectiveness ratio of adefovir dipivoxil vs. lamivudine (cost per additional responding patient with adefovir dipivoxil) was €27 872, demonstrating that this cost was slightly lower than the average cost-effectiveness ratios of adefovir dipivoxil or lamivudine. The sensitivity analysis demonstrated that the factors that most influence the cost-effectiveness were the response to adefovir dipivoxil and lamivudine at year 4. Conclusion

Long-term treatment with adefovir dipivoxil is a cost-effective strategy in patients with chronic hepatitis B `e' antigen-negative hepatitis.

Document Type: Research article

DOI: 10.1111/j.1365-2036.2006.02767.x

Affiliations: 1: Department of Hepatology, Hospital Vall d'Hebrón, Barcelona 2: Health Outcomes Research Unit, Pharmacoeconomics and Outcomes Research Iberia, Madrid 3: Department of Digestive Diseases, Hospital Puerta Hierro, Madrid 4: Department of Digestive Diseases, Hospital Clínico San Cecilio, Granada 5: Department of Digestive Diseases, Hospital Virgen del Rocio, Seville 6: Medical Department, Gilead Sciences Inc., Madrid, Spain

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on InterScience.

You may be required to register and activate access on InterScience before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B